# Clinical Trial Results

| | |
|---|---|
| **Clinical Trial Protocol Number** | EMR200559-005 |
| **Title** | A Phase III, Randomized, Double-Blind, Double Dummy, Multicenter Trial Comparing the Efficacy and Safety of 2 Doses of Daily Oral ONO 4641 (0.05 mg and 0.1 mg) versus Interferon-β-1a 30 µg IM Weekly in Subjects with Relapsing Multiple Sclerosis |
| **Trial Phase** | III |
| **EudraCT Number** | 2013-003126-83 |
| **Sponsor*** | Merck KGaA<br>Frankfurter Strasse 250, 64293, Darmstadt, Germany |
| **Primary Objectives** | The primary objective of this trial is to demonstrate the effect of ONO 4641 versus IFN β 1a (Avonex) 30 µg on the proportion of subjects, with RMS, who remain qualifying relapse–free during their participation in the trial when the last evaluable subject completes 1 year. |
| **Overall Trial Status** | Prematurely Ended (no patients have been enrolled) |
| **Reason for Trial Cancellation** | Discontinuation of development program. |

*On June 17, 2014 Merck announced that it has reached a mutual agreement with Ono Pharmaceutical Co., Ltd., Osaka, Japan, to terminate the license agreement on ceralifimod (ONO-4641)

https://www.merckgroup.com/press-releases/2014/jun/en/Ono-Pharmaceutical-Ceralifimod-EN.pdf